Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Non-cash Items (2020 - 2023)

Historic Non-cash Items for Cytek Biosciences (CTKB) over the last 4 years, with Q2 2023 value amounting to $4.4 million.

  • Cytek Biosciences' Non-cash Items fell 8707.05% to $4.4 million in Q2 2023 from the same period last year, while for Jun 2023 it was $4.4 million, marking a year-over-year decrease of 8707.05%. This contributed to the annual value of $37.2 million for FY2022, which is 7480.07% down from last year.
  • Latest data reveals that Cytek Biosciences reported Non-cash Items of $4.4 million as of Q2 2023, which was down 8707.05% from $30.9 million recorded in Q1 2023.
  • In the past 5 years, Cytek Biosciences' Non-cash Items registered a high of $63.9 billion during Q3 2022, and its lowest value of $1.0 million during Q2 2020.
  • For the 4-year period, Cytek Biosciences' Non-cash Items averaged around $5.4 billion, with its median value being $21.1 million (2020).
  • Per our database at Business Quant, Cytek Biosciences' Non-cash Items soared by 14951594.38% in 2022 and then crashed by 8707.05% in 2023.
  • Quarter analysis of 4 years shows Cytek Biosciences' Non-cash Items stood at $11.4 million in 2020, then soared by 1194.37% to $147.6 million in 2021, then plummeted by 74.8% to $37.2 million in 2022, then crashed by 88.22% to $4.4 million in 2023.
  • Its last three reported values are $4.4 million in Q2 2023, $30.9 million for Q1 2023, and $37.2 million during Q4 2022.